Upregulated CD36 expression has been observed in multiple cancer types, including acute myeloid leukemia, colon cancer, breast cancer, gastric cancer, etc. Altered CD36 protein levels lead to the activation of TGF signaling and hypoxia-induced factor-1 signaling, making MCT4 (mono-carboxylate transporter 4) active, which forms tumors. This evidence concerns the gene CD36 and breast cancer.